Back
to home » Treatment News » Top Stories
 March 30, 2011
|
March 29, 2011
|
New Viramune Tablet Approved for Once-Daily Use
Viramune XR—an extended-release version of nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI)—has been approved by the U.S. Food and Drug Administration (FDA), according to a March 28 announcement from the agency. The new Viramune formulation allows for once-daily dosing, an option that hasn’t been recognized by the FDA until now.
|
|
|
March 28, 2011
|
Pooled Trial Results Suggest Capsaicin Patch Relieves Neuropathy Pain
The pooled results of two clinical trials suggest that a skin patch with the chili pepperderived chemical capsaicin could relieve HIV-related neuropathy pain by about 30 percent. These trial results, presented at the annual meeting of the American Academy of Pain Medicine (AAPM), were reported by the website Medpage Today.
|
|
|
| March 24, 2011
|
March 23, 2011
|
Gilead’s Elvitegravir Showing Well in HIV Study
Gilead Sciences’ experimental integrase inhibitor elvitegravir appears to be working well in a Phase III clinical trial involving treatment-experienced patients, according to a March 23 press release by the company. Though the study will last about two years (96 weeks), Gilead says the study’s primary goal has been met: comparable results between patients receiving either elvitegravir or Merck’s approved integrase inhibitor Isentress (raltegravir) for 48 weeks.
|
|
|
March 22, 2011
|
Study Shows High Satisfaction and Success With Internet-Based HIV Care
A group of HIV-positive people who received their health care via the Internet from a Barcelona HIV clinic felt that their care was comparable with—and potentially superior to—standard in-person care. These findings, published January 21 in the online journal PLoS One and reported March 21 on the website Computerworld, could offer hope to select patients in rural settings who must often travel great distances to receive specialty HIV care.
|
|
|
March 21, 2011
|
MRSA Infections Are Now Falling in People With HIV
Researchers in Atlanta report that cases of methicillin-resistant Staphylococcus aureus (MRSA), an aggressive and difficult-to-treat bacterial infection, have dropped considerably since 2007. These data, published March 17 in the journal AIDS, could signal the beginnings of a reversal of a trend of sharp increases in the infection during the past decade, particularly among HIV-positive men who have sex with men (MSM).
|
|
|
March 18, 2011
|
Experts Propose Transmissible Gene Therapy to Halt the HIV Epidemic
Researchers have outlined an intriguing model that could help slow the spread of HIV better than test-and-treat models or a modestly effective HIV vaccine. Their theory, published online March 17 in the journal PLoS Computational Biology and reported by aidsmap, details how a gene therapy that curbs HIV production could be given to people with HIV. If these people were to have unsafe sex with someone else, they would pass along the gene therapy, essentially limiting the effects of HIV if the virus were to take hold in their sex partner.
|
|
|
March 17, 2011
|
U.S. Kids Born With HIV Are Doing Fairly Well as Teens
A recent study has found that most HIV-positive adolescents originally infected at or near birth in the United States have undetectable viral loads and fairly good immune health. The paper, published online March 9 in the Journal of Acquired Immune Deficiency Syndromes, also reports that children born around the time that combination therapy became the norm in the late 1990s are doing better than kids born when therapy was limited to one or two of the older antiretroviral (ARV) drugs.
|
|
|
March 16, 2011
|
Telaprevir, Boceprevir for Hep C Approaching FDA Finish Line
Two experimental hepatitis C virus protease inhibitors are scheduled to undergo approval review by the U.S. Food and Drug Administration’s Antiviral Drugs Advisory Committee at the end of April, according to a report from Dow Jones Newswires.
|
|
|
March 15, 2011
|
Personalized Text Messages Could Boost HIV Medication Adherence
A personalized text messaging reminder service significantly boosted antiretroviral (ARV) adherence over a six-week period compared with a standard beeper reminder system, according to a study published in the March issue of AIDS Patient Care and STDs. Though the authors acknowledge the small size of the study, they also indicate that the findings offer hope for the large number of people who struggle with adherence.
|
|
|
March 14, 2011
|
Increased Rates of Bone Fracture in Some People With HIV
People with HIV have higher rates of bone fractures than HIV-negative people of the same age, according to a study published March 10 in Clinical Infectious Diseases. The risk is highest in those with low CD4 counts and people who also have diabetes or hepatitis C virus (HCV).
|
|
|
|
|
|
 |
|
